Healthcare AI Governance Operating Model

Author: IT Modality editorial team

A workable lifecycle is:

1. frame the mandate and decision rights;

2. inventory the use case and dependencies;

3. map context, risk, and required reviewers;

4. measure the evidence that matters to the intended use;

5. decide with conditions and an accountable implementation owner; and

6. monitor, change, pause, or retire the capability as its context evolves.

Method boundary: This is a applied IT Modality operating synthesis, not a regulation, clinical recommendation, completed client method, or assurance that a particular system is safe or permissible.

Four source lessons—and what they do not decide

Sourced fact — NIST supplies a general risk language, not a hospital approval. NIST describes AI RMF 1.0 as voluntary and organizes its Core around Govern, Map, Measure, and Manage, with governance crossing the other functions; NIST also states that version 1.0 is being revised. (NIST AI Risk Management Framework and AI RMF Core, accessed 2026-07-11.)

Inference: A healthcare organization can use those functions as a common grammar, but the framework does not assign the organization's clinical, operational, legal, privacy, security, procurement, or deployment authority. The local charter must do that.

Sourced fact — generative AI adds a profile, not a universal risk score. NIST AI 600-1 is a cross-sectoral companion to AI RMF 1.0 for generative AI risk management. (NIST Generative AI Profile, accessed 2026-07-11.)

Inference: The inventory should distinguish generative behavior and foundation-model dependencies, but the profile does not make every generative use case equivalent or prescribe one hospital tiering scheme.

Sourced fact — a specific certified-health-IT criterion has a bounded scope. ASTP/ONC's test method for 45 CFR 170.315(b)(11) says certified health IT developers must apply intervention risk-management practices to each predictive decision-support intervention they supply as part of the certified module; the listed practices address risk analysis, mitigation, and governance, and the criterion also addresses source attributes. (ASTP/ONC Decision Support Interventions test method, accessed 2026-07-11.)

Boundary: That criterion is not a blanket certification of every local AI use, every third-party model, or the healthcare organization's broader governance program. The actual module, intervention, supplying party, certification status, and obligations need qualified review.

Sourced fact — “decision support” is not one regulatory category. FDA explains that some clinical-decision-support functions are excluded from the device definition while others remain device functions or may fall under other digital-health policies; FDA cautions that its CDS guidance should not be used as the sole reference. (FDA Clinical Decision Support Software FAQs, accessed 2026-07-11.)

Inference: Intake must capture intended use and output behavior early enough to route a function for qualified regulatory review. An internal “low-risk” label is not a regulatory conclusion.

Begin with authority, not a committee calendar

applied IT Modality method

Write a one-page charter before designing forms or scorecards. It should answer:

• Which AI-enabled capabilities enter the process: acquired products, embedded vendor features, locally developed models, generative assistants, automation, pilots, research, and material changes?

• Which uses are outside the process, and who may change that boundary?

• Who owns the portfolio, a use case, the workflow, the data, the technical system, the decision, implementation, monitoring, and incident escalation?

• Which reviewers are required by context rather than by title alone?

• Which dispositions exist: decline, return for evidence, approve a bounded test, approve with conditions, approve for a defined scope, pause, suspend, retire, or escalate?

• What can an urgent pathway change, and what cannot it waive?

• Where is the durable record, and who can view or change it?

The sponsor owns the mandate and unresolved conflict. The governance body owns the process and recorded disposition. The use-case owner owns the purpose and evidence. The implementation owner owns the approved change in the real workflow. Specialist reviewers own only conclusions within their authority. No committee vote silently transfers those responsibilities.

Inventory enough context to make a decision

applied IT Modality method

One durable use-case record should contain at least:

Identity and purpose

• stable use-case ID, name, owner, sponsor, status, and version;

• problem, intended benefit, current alternative, users, affected people, and excluded uses;

• clinical, operational, administrative, research, education, or other context;

• decision being supported or automated and the human authority that remains.

System and supply chain

• product, developer, vendor, host, model/provider, version, deployment pattern, and material subcontractor or external-service dependency;

• whether the capability is embedded, configured, fine-tuned, retrieval-augmented, locally developed, or otherwise changed;

• inputs, outputs, integrations, data flows, environments, logging, and failure dependencies;

• source attributes, model/system documentation, contract rights, update notices, support, and exit/data-return terms actually available.

People, workflow, and consequence

• where the output appears, who sees it, what action may follow, and how time-sensitive the decision is;

• who can contest, override, report, or correct the output;

• populations, sites, workflows, or conditions represented in evidence and those outside it;

• plausible harm, scale, reversibility, detectability, and downstream dependency if the output is wrong, missing, delayed, stale, insecure, or used beyond scope.

Evidence and controls

• claimed performance and its population, comparator, period, environment, uncertainty, and source;

• local validation question, method, acceptance condition, exception handling, and reviewer;

• privacy, security, data-use, retention, access, legal/regulatory, safety, usability, equity, and operational evidence as applicable;

• training, communication, support, downtime, rollback, monitoring, incident, change, and retirement plans.

Unknown is a valid value when it is paired with an owner, decision impact, evidence request, and due condition. A blank field is not a risk control.

Tier the review by consequence and uncertainty

applied IT Modality method

A tier should allocate review effort; it should not disguise a conclusion. Use a small set of questions before applying any numeric score:

1. What can the output cause? Consider direct action, delayed action, prioritization, documentation, communication, access, payment, employment, research, or another consequence.

2. Who can be affected and at what scale? Name people, roles, sites, and downstream systems rather than using “users” as a catchall.

3. Can a qualified person understand, contest, and recover? A nominal human in the loop is not enough if the person lacks time, information, authority, or an alternative.

4. How strong is the evidence for this context? Distinguish vendor claims, published evidence, technical tests, local workflow validation, and post-deployment observation.

5. What changes outside organizational control? Include model/provider releases, prompts, retrieval sources, interfaces, configurations, data drift, and contract/support changes.

6. Which specialist determination is required? Do not convert clinical, legal, regulatory, privacy, security, labor, procurement, or records judgment into a generic governance score.

The initial triage produces a review plan: required owners, evidence, tests, reviewers, conditions, and the next decision. It may also produce an immediate stop when the purpose is prohibited, accountability is absent, the intended use cannot be bounded, required evidence is unavailable, or recovery is not credible.

Record why the decision is supportable—and where it is not

applied IT Modality method

The decision packet should be short enough to use and complete enough to audit:

• approved purpose, scope, users, sites, population, workflow, version, and period;

• evidence reviewed, evidence not available, and important uncertainty;

• required controls and which are operating, tested, or still conditions;

• named implementation and monitoring owners;

• acceptance tests and the exact evidence for each;

• known limitations, excluded uses, escalation path, and stop triggers;

• decision, decision makers, dissent or unresolved issue, date, expiry/review-by date, and change threshold.

An approval is not “AI approved.” It is a bounded permission for the recorded version and use under stated conditions. A return-for-evidence disposition is not an informal approval. A pilot is not permission to spread beyond the pilot boundary.

Governance continues after the meeting

applied IT Modality method

Assign one implementation owner to translate the decision into the operating environment. The implementation plan should connect:

• configuration, integration, identity/access, data, environment, and release work;

• workflow placement, user roles, escalation, override, documentation, and downtime behavior;

• training for intended users and distinct guidance for supervisors, support, privacy/security, and incident responders;

• communication of scope and limitations without promotional shorthand;

• validation in the agreed context and evidence that acceptance conditions were met;

• go/no-go authority, rollback, support ownership, and the first monitoring review.

Adoption is not log-in count alone. Ask whether the intended users can identify when the capability applies, understand the output and limitations needed for their role, take the correct next action, report a problem, and use the fallback when the capability is unavailable or inappropriate.

Treat approval as a versioned state

applied IT Modality method

Monitoring should follow the failure modes and assumptions recorded at review. Depending on the use case, that can include input/context change, output quality, exceptions, overrides, workflow workarounds, user reports, access/security signals, vendor/model changes, support incidents, affected-group differences, and downstream effects. The record should state what is measured, from which source, at what cadence, by whom, with which threshold and disposition.

Change control begins with a trigger list. A new model, material version, purpose, population, data source, prompt/system instruction, retrieval corpus, integration, workflow placement, output, vendor term, or incident may require a return to inventory, testing, specialist review, or decision. The trigger depends on the use case; a deployment timestamp is not sufficient change analysis.

Incident handling should distinguish immediate operational containment from the later determination of clinical, privacy, security, regulatory, contractual, or other consequences. Retirement should name data/export needs, user and workflow transition, integration/access removal, vendor actions, retained evidence, support close, and the owner who verifies the capability is no longer in use.

CALIBRATED WORKED EXAMPLE

What one decision record can make visible

This example shows record structure only. It does not imply that the fictional use is safe, permitted, effective, available as a product, or delivered for any organization.

Start with ten use cases, not an enterprise policy rewrite

applied IT Modality method

For a bounded first pass:

1. Name the sponsor, process owner, and decision authority.

2. Select a mixed set of current, current, embedded, paused, and unknown AI-enabled uses.

3. Build the minimum record without forcing unknowns into optimistic values.

4. Group by consequence, uncertainty, and required specialist review.

5. Trace one use case from intake through implementation, monitoring, change, and retirement.

6. Identify where ownership, evidence, or system visibility breaks.

7. Define the smallest artifacts and gates that repair those breaks.

8. Assign owners and a review condition before adding more inventory.

Stop expansion when the organization cannot name decision authority, distinguish real inventory from rumor, access essential vendor/system evidence, keep production data out of an unapproved test, or operate the review and monitoring path.

Primary sources used in this guide

• NIST, “AI Risk Management Framework” and the AI RMF Core. Voluntary framework, current revision notice, and Govern/Map/Measure/Manage structure. Accessed 2026-07-11. Revalidate by 2026-10-11. Framework · Core

• NIST, “Artificial Intelligence Risk Management Framework: Generative Artificial Intelligence Profile,” NIST AI 600-1. Cross-sectoral companion profile. Accessed 2026-07-11. Revalidate by 2026-10-11. Source

• ASTP/ONC, “Decision support interventions,” 45 CFR 170.315(b)(11) test method. Bounded certified-health-IT criterion, source attributes, and intervention risk-management requirements. Accessed 2026-07-11. Revalidate by 2026-10-11. Source

• FDA, “Clinical Decision Support Software Frequently Asked Questions.” Device/non-device CDS policy context and limits. Accessed 2026-07-11. Revalidate by 2026-10-11. Source

Source limitation: These sources have different scopes and authorities. They do not collectively approve a use case or replace qualified clinical, regulatory, legal, privacy, security, procurement, records, or operational review. NIST states that AI RMF 1.0 is being revised, so the article is revalidated on the stated review cycle and whenever a material revision changes the cited guidance. (NIST AI RMF page, accessed 2026-07-11.)

Correction path: Report a source, reasoning, or accessibility concern